Prosthetic groups attached to stannyl polymer in the synthesis of radiopharmaceuticals
The present invention relates to compositions and methods for preparing radiopharmaceutical compounds in high chemical-purity and isotopic-purity. The present invention provides polymer-bound precursors to radiopharmaceutical compounds that can be converted to radiopharmaceutical compounds in one step. In a preferred embodiment, a radiopharmaceutical precursor is bound to a polymeric support via a prosthetic group comprising an alkenyl-tin bond. The radiopharmaceutical precursor is converted to a radiopharmaceutical compound in one step involving cleavage of the alkenyl-tin bond and incorporation of a radioisotope to form the radiopharmaceutical compound. Importantly, the polymeric support containing the toxic tin by-product can be easily removed from the radiopharmaceutical compound by filtration. The present invention can be used to install a large number of different radioisotopes. In a preferred embodiment, the radioisotope is 211 At, 123 I or 131 I.
1. A compound represented by formula 1:
wherein
Poly represents a polymer selected from the group polyethylene glycol, polystyrene, polyamide, polypeptide, polyurethane, poly(ethylene-co-vinyl acetate), polyethylene, polystyrene/rubber and poly(ethylene-co-propylene);
R 1 represents alkenyl;
R 2 represents —NR 4 R 5 , phosphate, phosphite, phosphine, XR 5′ , Z, or R 2 is represented by formula 2:
wherein m is 1-8; R represents independently for each occurrence hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyl, alkoxyl, silyloxy, amino, nitro, sulfhydryl, alkylthio, imine, phosphoryl, phosphonate, phosphine, carboxamide, anhydride, silyl, thioalkyl, alkylslIifonyl, arylsulfonyl, selenoalkyl, heteroalkyl, nitrile, guanidine, amidine, acetal, ketal, amine oxide, aryl, heteroaryl, azide, aziridine, epoxide, hydroxamic acid, imide, oxime, sulfonamide, —COR 6 , —C(O) 2 R 6 , —C(O)N(R 6 ) 2 , —N(R 6 )C(O)R 6 , —OC(O)N(R 6 ) 2 , —N(R 6 )C(O) 2 R 7 , —C(S)N(R 6 ) 2 , —N(R 6 )C(S)R 6 , —OC(S)N(R 6 ) 2 , —N(R 6 )C(S)OR 7 , —N(R 6 )C(O)N(R 6 ) 2 , —N(R 6 )C(S)N(R 6 ) 2 , or —(CH 2 ) q —R 80 ; wherein q is 1-10; R 80 represents an optionally substituted aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl; R 6 represents independently for each occurence H, alkyl, alkenyl, aryl, or aralkyl; and R 7 represents independently for each occurrence alkyl, alkenyl, aryl, or aralkyl;
X is S, Se, or AsR 5 ;
Z is a malonate, β-ketoester, α-nitroester, α-cyanoester, α-phosphonoester, or α-ketophosphonate;
n is 1-15;
R 3 represents independently for each occurrence alkyl, aralkyl, alkenyl or alkynyl;
R 4 and R 5 represent independently for each occurrence hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; and
R 5′ represents alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
2. The compound of claim 1 , wherein n is 1-5.
3. The compound of claim 1 , wherein n is 1.
4. The compound of claim 1 , wherein R 1 is —CH═CH—.
5. The compound of claim 1 , wherein R 3 is alkyl.
6. The compound of claim 1 , wherein R 3 is n-butyl.
7. The compound of claim 1 , wherein R 1 is —HC═CH—, R 3 is alkyl, n is 1, poly is polystyrene, and R 2 is —NR 4 R 5 .
8. The compound of claim 1 , wherein R 2 is —NR 4 R 5 or XR 5′ .
9. The compound of claim 1 , wherein R 2 is —NR 4 R 5 .
10. The compound of claim 1 , wherein R 2 is an amino group of a nucleotide, nucleoside, nucleic acid, carbohydrate, purine, pyrimidine or amino acid.
11. The compound of claim 1 , wherein R 1 is —HC═CH—, R 3 is alkyl, n is 1, said polymer is polystyrene, and R 2 is optionally substituted 1-piperidinyl.
12. The compound of claim 1 , wherein R 2 is XR 5′ , wherein X is S.
13. The compound of claim 1 , wherein the polymer of structure 1 is functionalized by the moiety —Sn(R 3 ) 2 R 1 (CH 2 )nR 2 on a plurality of monomeric units of the polymer.
14. The compound of claim 1 , wherein R 2 is an amino group of a peptide.
15. The compound of claim 1 , wherein R 2 is an amino group of an antibody.
16. The compound of claim 1 , wherein poly is polystyrene.
17. The compound of claim 1 , wherein R 2 is represented by formula 2:
wherein m is 3 or 4; R represents independently for each occurrence hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyl, alkoxyl, silyloxy, amino, nitro, sulfhydryl, alkylthio, imine, phosphoryl, phosphonate, phosphine, carboxamide, anhydride, silyl, thioalkyl, alkylsulfonyl, arylsulfonyl, selenoalkyl, heteroalkyl, nitrile, guanidine, amidine, acetal, ketal, amine oxide, aryl, heteroaryl, azide, aziridine, epoxide, hydroxamic acid, imide, oxime, sulfonamide, —COR 6 , —CO 2 R 6 , —C(O)N(R 6 ) 2 , —N(R 6 )C(O)R 6 , —OC(O)N(R 6 ) 2 , —N(R 6 )CO 2 R 7 , —C(S)N(R 6 ) 2 , —N(R 6 )C(S)R 6 , —OC(S)N(R 6 ) 2 , —N(R 6 )C(S)OR 7 , —N(R 6 )C(O)N(R 6 ) 2 , —N(R 6 )C(S)N(R 6 ) 2 , or —(CH 2 ) q —R 80 ; wherein q is 1-10; R 80 represents an optionally substituted aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl; R 6 represents independently for each occurence H, alkyl, alkenyl, aryl, or aralkyl; R 7 represents independently for each occurrence alkyl, alkenyl, aryl, or aralkyl; and poly is polystyrene.
18. A method of synthesizing a polymer-bound prosthetic, group, wherein the polymer-bound prosthetic group is the compound of claim 1 , comprising the steps of:
combining a first compound and a polymer to give a first polymer-bound compound; and combining a second compound with said first polymer-bound compound to give a second polymer-bound compound comprising a functionalized prosthetic group, wherein said second compound is an amine, phosphate, phosphite, phosphine, alcohol, phenol, thiol, alkylselenide, arylselenide, bis(alkyl)arsenide, bis(aryl)arsenide, malonate, β-ketoester, α-nitroester, α-cyanoester, α-phosphonoester, or α-ketophosphonate, or an anion derived from any of them; said polymer comprises a tin chloride moiety; and said first compound is represented by formula 3:
M-R 1 —(CH 2 ) n —R 2 3
wherein
M is a cation;
R 1 represents alkenyl;
R 2 is OSi(alkyl) 3 , OMEM, acyloxy, or OBn; and
n is 1-15.
19. The method of claim 18 , wherein n is 1-5.
20. The method of claim 18 , wherein n is 1.
21. The method of claim 18 , wherein M is an alkali metal cation or alkaline earth metal cation.
22. The method of claim 18 , wherein M is Li, Na, K, ZnCl, ZnBr, MgBr, or MgCl.
23. The method of claim 18 , wherein R 2 is OSi(alkyl) 3 .
24. The method of claim 18 , wherein R 2 is OSi(iPr) 3 .
25. The method of claim 18 , wherein R 1 is —CH═CH—.
26. The method of claim 18 , wherein said second compound is an amine, alcohol, phenol, thiol, malonate, β-ketoester, or an anion derived from any of them.
27. The method of claim 18 , wherein said second compound is an amine, alcohol, or an anion derived from any of them.
28. The method of claim 18 , wherein said second compound is an amine or an anion derived therefrom.
29. The method of claim 18 , wherein said functionalized prosthetic group is represented by formula 2:
wherein m is 1-8; R represents independently for each occurrence hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyl, alkoxyl, silyloxy, amino, nitro, sulfhydryl, alkylthio, imine, phosphoryl, phosphonate, phosphine, carboxamide, anhydride, silyl, thioalkyl, alkylsulfonyl, arylsulfonyl, selenoalkyl, heteroalkyl, nitrile, guanidine, amidine, acetal, ketal, amine oxide, aryl, heteroaryl, azide, aziridine, epoxide, hydroxamic acid, imide, oxime, sulfonamide, —COR 6 , —CO 2 R 6 , —C(O)N(R 6 ) 2 , —N(R 6 )C(O)R 6 , OC(O)N(R 6 ) 2 , —N(R 6 )CO 2 R 7 , —C(S)N(R 6 ) 2 , —N(R 6 )C(S)R 6 , —OC(S)N(R 6 ) 2 , —N(R 6 )C(S)OR 7 , —N(R 6 )C(O)N(R 6 ) 2 , —N(R 6 )C(S)N(R 6 ) 2 , or —(CH 2 ) q —R 80 ; wherein q is 1-10; R 80 represents an optionally substituted aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl; R 6 represents independently for each occurrence H, alkyl, alkenyl, aryl, or aralkyl; and R 7 represents independently for each occurrence alkyl, alkenyl, aryl, or aralkyl.
30. The method of claim 18 , wherein said functionalized prosthetic group is represented by formula 2:
wherein m is 3 or 4; R represents independently for each occurrence hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyl, alkoxyl, silyloxy, amino, nitro, sulfhydryl, alkylthio, imine, phosphoryl, phosphonate, phosphine, carboxamide, anhydride, silyl, thioalkyl, alkylsulfonyl, arylsulfonyl, selenoalkyl, heteroalkyl, nitrile, guanidine, amidine, acetal, ketal, amine oxide, aryl, heteroaryl, azide, aziridine, epoxide, hydroxamic acid, imide, oxime, sulfonamide, —COR 6 , —CO 2 R 6 , —C(O)N(R 6 ) 2 , —N(R 6 )C(O)R 6 , OC(O)N(R 6 ) 2 , —N(R 6 )CO 2 R 7 , —C(S)N(R 6 ) 2 , —N(R 6 )C(S)R 6 , —OC(S)N(R 6 ) 2 , —N(R 6 )C(S)OR 7 , —N(R 6 )C(O)N(R 6 ) 2 , —N(R 6 )C(S)N(R 6 ) 2 , or —(CH 2 ) q —R 80 ; wherein q is 1-10; R 80 represents an optionally substituted aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl; R 6 represents independently for each occurrence H, alkyl, alkenyl, aryl, or aralkyl; and R 7 represents independently for each occurrence alkyl, alkenyl, aryl, or aralkyl.
31. The method of claim 18 , wherein said functionalized prosthetic group is optionally substituted 1-piperidinyl.
32. The method of claim 18 , wherein said polymer comprises a tin chloride moiety and polyethylene glycol, polystyrene, polyamide, or polypeptide.
33. The method of claim 18 , wherein said polymer comprises a tin chloride moiety and polystyrene, polyurethane, poly(ethylene-co-vinyl acetate), polyethylene, polystyrene/rubber, or poly(ethylene-co-propylene).
34. The method of claim 18 , wherein said polymer comprises a tin chloride moiety and polystyrene.
35. The method of claim 18 , wherein said polymer comprises a dibutyltin chloride moiety and polystyrene.
36. A method for preparing a radiopharmaceutical compound from a polymer-bound compound comprising a functionalized prosthetic group, comprising the steps of:
mixing a radioisotope, an oxidant, and a polymer-bound compound comprising a functionalized prosthetic group, wherein said polymer-bound compound comprising a functionalized prosthetic group is represented by formula 1:
wherein
Poly represents a polymer selected from the group polyethylene glycol, polystyrene, polyamide, polypeptide, polyurethane, poly(ethylene-co-vinyl acetate), polyethylene, polystyrene/rubber and poly(ethylene-co-propylene);
R 1 represents alkenyl:
R 2 represents —NR 4 R 5 , phosphate, phosphate, phosphine, XR 5′ , Z, or R 2 is represented by formula 2:
wherein m is 1-8; R represents independently for each occurrence hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxyl, alkoxyl, silyloxy, amino, nitro, sulfhydryl, alkylthio, imine, phosphoryl, phosphonate, phosphine, carboxamide, anhydride, silyl, thioalkyl, alkylsulfonyl, arylsulfonyl, selenoalkyl, heteroalkyl, nitrile, guanidine, amidine, acetal, ketal, amine oxide, aryl, heteroaryl, azide, aziridine, epoxide, hydroxamic acid, imide, oxime, sulfonamide, —COR 6 , —CO 2 R 6 , —C(O)N(R 6 ) 2 , —N(R 6 )C(O)R 6 , —OC(O)N(R 6 ) 2 , —N(R 6 )CO 2 R 7 , —C(S)N(R 6 ) 2 , —N(R 6 )C(S)R 6 , —OC(S)N(R 6 ) 2 , —N(R 6 )C(S)OR 7 , —N(R 6 )C(O)N(R 6 ) 2 , —N(R 6 )C(S)N(R 6 ) 2 , or —(CH 2 ) q —R 80 ; wherein q is 1-10; R 80 represents an optionally substituted aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl; R 6 represents independently for each occurrence H, alkyl, alkenyl, aryl, or aralkyl; and R 7 represents independently for each occurrence alkyl, alkenyl, aryl, or aralkyl;
X is S, Se, or AsR 5 ;
Z is a malonate, β-ketoester, α-nitroester, α-cyanoester, α-phosphonoester, or α-ketophosphonate;
n is 1-15;
R 3 represents independently for each occurrence alkyl, aralkyl, alkenyl or alkynyl;
R 4 and R 5 represent independently for each occurrence hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl,
aralkyl, or heteroaralkyl; and
R 5′ represents alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
37. The method of claim 36 , wherein said oxidant is chloramine-T in ethanol/water with or without acetic acid, N-chlorosuccinimide with acetic acid in methanol, tert-butylhydroperoxide with acetic acid in chloroform, lodogen with a phosphate buffer, or iodobeads with or without acetic acid in methanol.
38. The method of claim 36 , wherein said radioisotope is 18 F, 11 C, 76 Br, 211 At, 123 I, 131 I or 125 I.
39. The method of claim 36 , wherein said radioisotope is 211 At, 131 I, 123 I, or 18 F.
40. The method of claim 36 , wherein said radioisotope is 211 At.
41. The method of claim 36 , wherein said radioisotope, is 131 I.
42. The method of claim 36 , wherein said radiopharmaceutical compound formed by this process is produced at the no-carrier-added level and has a specific activity equal to about the specific activity level of the source of said radioisotope.
43. The method of claim 36 , wherein said radiopharmaceutical compound is isotopically pure.
44. The method of claim 36 , wherein said radiopharmaceutical compound is a radiolabeled peptide or protein; and said radiopharmaceutical compound isotopically pure.
45. The method of claim 36 , wherein said radiopharmaceutical compound is a radiolabeled antibody; and said radiopharmaceutical compound is isotopically pure.
46. The method of claim 36 , wherein said radiopharmaceutical compound is a radiolabeled nucleotide or nucleoside; and said radiopharmaceutical compound is isotopically pure.